Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PolyPreventHF: Polypill Strategy for Prevention of Heart Failure in Diabetes
NCT06143566Phase 2Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Mar 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin, losartan, finerenone in heart failure (HF), sponsored by UT Southwestern Medical Center. Started Mar 2024; status: recruiting.
02
Drugs
empagliflozinlosartanfinerenone
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06143566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06143566.